M
Meissa Vaccines
Meissa vaccines develops vaccines to protect people from life-threatening respiratory viruses
About Meissa Vaccines
Meissa Vaccines is a pharmaceutical startup dedicated to developing vaccines for serious human diseases, particularly respiratory syncytial virus (RSV) and rhinovirus. The company leverages innovative platform technology for viral genetic engineering, which can be applied to multiple pathogens. Meissa's primary focus is on child health, but its vaccine programs have the potential to benefit various age and population groups. The successful development of vaccines for RSV and related viruses promises widespread societal benefits, including alleviating serious lower respiratory tract diseases and reducing asthma and COPD exacerbations. Meissa operates in the pharmaceutical and biotech sectors, serving healthcare providers, hospitals, and potentially global health organizations. The business model revolves around research and development, clinical trials, and eventual commercialization of vaccines. Revenue is generated through partnerships, grants, and future sales of approved vaccines.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2019 | $30M | $120M | Morningside | — |
| SEED✓Equity / VC | Mar 2019 | $3.4M | $14M | Undisclosed | — |
Growth signals
Latest recorded traffic for Meissa Vaccines is 380 monthly website visits, up 31% over the last three months. Meissa Vaccines's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Meissa Vaccines in the San Francisco ecosystem
The Meissa Vaccines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
FundRx
Series A1 investor entered at this stage
Other known investors1 additional known investor
Emory University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Meissa Vaccines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Meissa Vaccines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










